Form 8-K - Current report:
SEC Accession No. 0001437749-23-008884
Filing Date
2023-03-31
Accepted
2023-03-31 17:20:13
Documents
16
Period of Report
2023-03-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20230331_8k.htm   iXBRL 8-K 32499
2 EXHIBIT 10.1 ex_495945.htm EX-10.1 32302
3 EXHIBIT 10.2 ex_495946.htm EX-10.2 38276
4 EXHIBIT 99.1 ex_495947.htm EX-99.1 14551
  Complete submission text file 0001437749-23-008884.txt   290318

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA navb-20230330.xsd EX-101.SCH 4035
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20230330_def.xml EX-101.DEF 13506
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20230330_lab.xml EX-101.LAB 17660
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20230330_pre.xml EX-101.PRE 13473
10 EXTRACTED XBRL INSTANCE DOCUMENT navb20230331_8k_htm.xml XML 4280
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 23789233
SIC: 2835 In Vitro & In Vivo Diagnostic Substances